UBT251 Achieves 2.16% HbA1c Reduction in Diabetes Trial

UBT251 achieves 2.16% HbA1c reduction in diabetes trial

GAUNG DONG, CHINA and BAGSVÆRD, DENMARK - Media OutReach Newswire - 25 March 2026 - The United Laboratories International Holdings Limited (TUL) and Novo Nordisk A/S (Novo Nordisk) today announced topline results from a Chinese phase 2 trial of UBT251, a triple agonist of the receptors for GLP-1, GIP, and glucagon (triple G). UBT251 is being jointly developed by TUL's wholly-owned subsidiary, The United Bio-Technology (Hengqin) Co., Ltd. (United…

Triple agonist UBT251 showed a mean HbA1c reduction of up to 2.16% after 24 weeks in phase 2 trial in Chinese patients with type 2 diabetes - European Business & Finance Magazine

UBT251 is a triple agonist of the receptors for GLP-1, GIP and glucagon (triple G), being jointly developed by United Biotechnology and Novo Nordisk In a phase 2 trial in Chinese people with type 2 diabetes, UBT251 showed a mean HbA1c reduction of up to 2.16%, and a mean body weight reduction of up to 9.8% after 24 weeks, showing improvements relative to placebo and semaglutide 1 mg The safety and tolerability profile of UBT251 appeared consiste…